Antiresorptive drugs have become the mainstay for the prevention and treatment of
osteoporosis. Members of this class include estrogen, the selective estrogen receptor …

Osteoclasts are specialized cells that initiate the process of bone resorption, which has two
phases, dissolution of the mineral component and degradation of the organic matrix, in …

Aims To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods Two double‐blind …

Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption
over bone formation, resulting in decreased bone mineral density and deterioration of bone …

Osteoporosis is a metabolic bone disease that is characterized by heightened state of bone
resorption accompanied by diminished bone formation, leading to a reduction of bone …

Odanacatib (MK· 0822, MK-822) is an orally administered cathepsin K inhibitor being
developed by Merck & Co Inc, under license from Ce/era Croup, for the treatment of …

Background Selective and reversible inhibitors of human Cathepsin K (CatK), including
odanacatib (ODN), have been developed as potential therapeutics for the treatment of …

The efficacy and safety of oral placebo or odanacatib 10, 25, or 50 mg once weekly for 52
weeks were evaluated in a double-blind, randomized, multi-center study in Japanese female …

Human bones are in a continuous process of remodeling that ensures renovation and
maintenance of the skeletal mass. Bone remodeling has two phases that are normally …